Oxford BioDynamics (LON:OBD) Shares Down 10.2% – Should You Sell?

Oxford BioDynamics Plc (LON:OBD) was down 10.2% during mid-day trading on Friday . The company traded as low as GBX 0.28 and last traded at GBX 0.28. Approximately 27,311,211 shares changed hands during trading, an increase of 4% from the average daily volume of 26,257,648 shares. The stock had previously closed at GBX 0.32.

Oxford BioDynamics Stock Down 5.2%

The business’s 50 day moving average is GBX 0.26 and its 200 day moving average is GBX 0.35. The company has a market cap of £11.80 million, a P/E ratio of -0.34 and a beta of 0.42. The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings data on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.